| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
57,667 |
47,642 |
$3.52M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
40,420 |
32,056 |
$1.68M |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
27,324 |
21,574 |
$1.52M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
25,613 |
21,739 |
$651K |
| 87634 |
|
7,215 |
5,932 |
$318K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
12,478 |
9,894 |
$255K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
4,440 |
3,467 |
$252K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
7,153 |
5,269 |
$192K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
15,657 |
7,114 |
$173K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
14,223 |
12,014 |
$146K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,752 |
1,392 |
$143K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
4,598 |
3,766 |
$122K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
2,527 |
2,157 |
$110K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
11,001 |
8,694 |
$106K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
2,475 |
1,908 |
$32K |
| Q3014 |
Telehealth originating site facility fee |
2,202 |
1,809 |
$30K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
4,196 |
3,635 |
$21K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
342 |
252 |
$21K |
| 80061 |
Lipid panel |
2,183 |
2,051 |
$21K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
2,924 |
2,719 |
$18K |
| 80076 |
|
2,621 |
2,452 |
$15K |
| 87807 |
|
1,577 |
1,422 |
$14K |
| 99490 |
Ccm add 20min |
973 |
970 |
$8K |
| 36415 |
Collection of venous blood by venipuncture |
5,418 |
4,665 |
$7K |
| 81003 |
|
4,978 |
4,211 |
$7K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
5,080 |
4,071 |
$6K |
| 74018 |
|
331 |
300 |
$6K |
| 87428 |
|
113 |
108 |
$5K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
591 |
560 |
$4K |
| 84443 |
Thyroid stimulating hormone (TSH) |
240 |
217 |
$3K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
80 |
45 |
$2K |
| 99385 |
|
33 |
30 |
$1K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
31 |
14 |
$1K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
12 |
12 |
$1K |
| 90756 |
|
71 |
56 |
$799.81 |
| 99215 |
Prolong outpt/office vis |
13 |
12 |
$744.47 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
187 |
87 |
$593.28 |
| 84479 |
|
124 |
108 |
$545.08 |
| 84436 |
|
111 |
95 |
$502.33 |
| 92551 |
|
92 |
59 |
$494.15 |
| 82043 |
|
134 |
106 |
$332.67 |
| 81025 |
|
69 |
56 |
$305.07 |
| 71046 |
Radiologic examination, chest; 2 views |
21 |
13 |
$272.84 |
| 96160 |
|
161 |
96 |
$262.86 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
508 |
381 |
$155.19 |
| 84439 |
|
32 |
22 |
$153.34 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$142.33 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
98 |
88 |
$136.59 |
| 93000 |
|
13 |
13 |
$134.05 |
| 99406 |
|
18 |
14 |
$128.39 |
| 96127 |
|
41 |
41 |
$111.48 |
| 99173 |
|
160 |
82 |
$93.09 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
306 |
233 |
$33.61 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
12 |
12 |
$26.88 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
17 |
17 |
$18.30 |
| 82607 |
|
18 |
13 |
$15.08 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
17,818 |
14,042 |
$6.90 |
| 3078F |
|
21,911 |
17,109 |
$0.00 |
| 3288F |
|
26,743 |
22,034 |
$0.00 |
| 1159F |
|
60,428 |
47,902 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
2,106 |
1,642 |
$0.00 |
| 3077F |
|
902 |
713 |
$0.00 |
| 1160F |
|
55,443 |
43,976 |
$0.00 |
| 4004F |
|
257 |
223 |
$0.00 |
| 99497 |
|
42 |
17 |
$0.00 |
| 1100F |
|
947 |
772 |
$0.00 |
| G9458 |
Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user |
86 |
60 |
$0.00 |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
44 |
24 |
$0.00 |
| 1158F |
|
412 |
299 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
396 |
309 |
$0.00 |
| G9624 |
Patient not screened for unhealthy alcohol use using a systematic screening method or patient did not receive brief counseling if identified as an unhealthy alcohol user |
21 |
20 |
$0.00 |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
46 |
24 |
$0.00 |
| G9622 |
Patient not identified as an unhealthy alcohol user when screened for unhealthy alcohol use using a systematic screening method |
266 |
175 |
$0.00 |
| G9923 |
Safety concerns screen provided and negative |
224 |
139 |
$0.00 |
| 1125F |
|
32,365 |
26,166 |
$0.00 |
| 1126F |
|
36,636 |
28,957 |
$0.00 |
| 1111F |
|
318 |
292 |
$0.00 |
| 3074F |
|
25,816 |
20,077 |
$0.00 |
| 3072F |
|
15,000 |
11,764 |
$0.00 |
| 3079F |
|
11,441 |
9,398 |
$0.00 |
| 1101F |
|
42,492 |
33,378 |
$0.00 |
| 3075F |
|
6,518 |
5,435 |
$0.00 |
| 1170F |
|
475 |
337 |
$0.00 |
| G8420 |
Bmi is documented within normal parameters and no follow-up plan is required |
3,754 |
2,991 |
$0.00 |
| G8422 |
Bmi not documented, documentation the patient is not eligible for bmi calculation |
6,086 |
4,820 |
$0.00 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
105 |
70 |
$0.00 |
| G2181 |
Bmi not documented due to medical reason or patient refusal of height or weight measurement |
206 |
177 |
$0.00 |
| 3080F |
|
408 |
329 |
$0.00 |
| 3061F |
|
337 |
252 |
$0.00 |
| 3011F |
|
52 |
49 |
$0.00 |
| G8418 |
Bmi is documented below normal parameters and a follow-up plan is documented |
119 |
94 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
143 |
119 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
12 |
12 |
$0.00 |
| 3049F |
|
18 |
16 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
14 |
13 |
$0.00 |
| 3048F |
|
19 |
18 |
$0.00 |